证券日报网讯12月15日，汉森制药（002412）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司含信用账户合并股东名册的股东总数为24145户。 ...

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) has indicated on its investor interaction platform that it offers products related to cold treatment, including Ganmao Qingre Granules, Baibei Yipeng Capsules, and Compound Acetaminophen and Amantadine Tablets [1] Company Summary - Hansen Pharmaceutical has a range of products aimed at treating cold symptoms [1] - The company includes wholly-owned subsidiaries in its product offerings [1]

Core Viewpoint - Hansen Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 17.64%, indicating strong market performance and investor interest [2]. Group 1: Stock Performance - As of December 3, Hansen Pharmaceutical's stock price increased by 2.02%, reaching 7.07 CNY per share, with a trading volume of 46.93 million CNY and a turnover rate of 1.35% [1]. - The stock has experienced a 2.61% increase over the last five trading days, a 7.45% increase over the last 20 days, and a 4.74% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Hansen Pharmaceutical reported a revenue of 741 million CNY, reflecting a year-on-year growth of 6.75%. However, the net profit attributable to shareholders decreased by 36.88% to 82.53 million CNY [2]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. Group 3: Business Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang, Hunan Province. Its main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The revenue composition of Hansen Pharmaceutical includes: 54.81% from Si Mo Tang oral liquid, 23.38% from Tian Ma Xing Nao capsules, and smaller contributions from various other products [2]. Group 4: Shareholder Information - As of November 28, 2025, the number of shareholders in Hansen Pharmaceutical increased to 24,100, with an average of 20,618 circulating shares per person, a slight decrease of 0.84% from the previous period [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is the eighth largest, holding 2.11 million shares as a new shareholder [3].

Group 1 - The 91st National Pharmaceutical Trade Fair was held in Nanjing from November 19-21, covering over 170,000 square meters with more than 8,200 exhibition booths and over 4,000 domestic and international companies participating [1] - The event featured over 70 forums and activities, with more than 550 industry experts and scholars discussing hot topics and future trends in the pharmaceutical industry [1] - Hunan Hansen Pharmaceutical Co., Ltd., a leading company in Hunan's pharmaceutical sector, showcased its products at the Hunan exhibition area, aiming to promote high-quality development in the industry [1] Group 2 - During the Nanjing Pharmaceutical Trade Fair, Hansen Pharmaceutical's core product, Hansen Si Mo Tang Oral Liquid, was awarded a spot on the "2024-2025 Annual Family Essential Medicine Brand" list due to its excellent efficacy and market reputation [2] - Hansen Pharmaceutical adheres to the corporate value of "treating consumers well and continuously providing good products," aiming to contribute more to the health of the Chinese population [2] - The Si Mo Tang Oral Liquid is a compound traditional Chinese medicine for gastrointestinal motility, included in the national medical insurance catalog and recognized as a protected traditional Chinese medicine product [2]

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) is currently in the process of scaling up the research for its new traditional Chinese medicine product, Cangrong Granules, which is in the stage of pilot testing [1] Group 1 - The company is focusing on research and development in the field of traditional Chinese medicine [1] - Cangrong Granules is a new drug under development by the company [1] - The current phase of research involves pilot testing for process scaling [1]

Group 1 - The company, Hansen Pharmaceutical, reported a total of 23,941 shareholders as of October 31, 2025, including those in credit accounts [2]

Core Viewpoint - The company has received a renewed Drug Production License from the Hunan Provincial Drug Administration, ensuring its continued operations until November 6, 2030 [1]. Group 1: License Information - The new Drug Production License is valid until November 6, 2030, with the license number 湘20150132 [1]. - The company is authorized to produce a variety of pharmaceutical forms, including large volume injections, small volume injections, tablets, hard capsules, granules, syrups, tinctures, and traditional Chinese medicine preparations [1]. Group 2: Company Impact - The renewal of the Drug Production License is a routine procedure due to the expiration of the previous license, and it does not have a significant impact on the company's performance [1].

证券日报网讯 11月17日晚间，汉森制药发布公告称，湖南汉森制药股份有限公司（以下简称"公司"） 近日收到湖南省药品监督管理局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效期至 2030年11月6日。 （文章来源：证券日报） ...

格隆汇11月17日丨汉森制药(002412.SZ)公布，近日收到湖南省药品监督管理局换发的《药品生产许可 证》，换发后的《药品生产许可证》的有效期至2030年11月06日，本次换发《药品生产许可证》是基于 原证即将到期，新证的取得确保了公司的正常生产经营，对公司业绩无重大影响。 ...

Core Points - Company obtained a new drug production license from Hunan Provincial Drug Administration, ensuring continued operations until November 6, 2030 [1] - The new license covers a wide range of products including large volume injections, small volume injections, tablets, hard capsules, granules, syrups, tinctures, mixtures, pills, and second-class psychotropic drugs [1] - The renewal of the license is based on the expiration of the previous one and does not have a significant impact on the company's performance [1]